SCHEMBL5934181

SCHEMBL5934181

COc1ccccc1-c1ccc(C(=O)Nc2ccc(Cl)c(Cl)c2)cn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 5/20 0.55
▸ KMT2A Q03164 5/20 0.55
▸ MAPT P10636 3/20 0.55
▸ KDM4E B2RXH2 2/20 0.55
▸ SMN1; SMN2 Q16637 2/20 0.55
▸ MITF O75030 1/20 0.55
▸ ALDH1A1 P00352 1/20 0.55
▸ LMNA P02545 1/20 0.55
▸ MAPK1 P28482 1/20 0.55
▸ HTT P42858 1/20 0.55
▸ NPC1 O15118 3/20 0.51
▸ RAB9A P51151 3/20 0.51
▸ GRM4 Q14833 3/20 0.51
▸ HDAC6 Q9UBN7 1/20 0.51
▸ PKM P14618 1/20 0.50
▸ AHR P35869 1/20 0.50
▸ KCNQ3 O43525 2/20 0.49
▸ KCNQ2 O43526 2/20 0.49
▸ KCNE1 P15382 1/20 0.49
▸ KCNQ1 P51787 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5934704 0.91 MAPT (0.54) MEN1KMT2AMAPTKDM4ESMN1; SMN2
SCHEMBL5934383 0.88 MEN1 (0.59) MEN1KMT2AMAPTKDM4ESMN1; SMN2
SCHEMBL5934279 0.86 NPC1 (0.58) MEN1KMT2AMAPTKDM4ELMNA
SCHEMBL5934470 0.86 RAB9A (0.53) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL5934567 0.85 RAB9A (0.54) MEN1KMT2AMAPTKDM4ESMN1; SMN2
SCHEMBL5934372 0.84 NPC1 (0.60) KMT2AKDM4ESMN1; SMN2ALDH1A1NPC1
SCHEMBL5934911 0.83 NPC1 (0.52) MEN1KMT2AMAPTKDM4ESMN1; SMN2
SCHEMBL5934543 0.83 NPC1 (0.54) MEN1KMT2AMAPTKDM4ELMNA
SCHEMBL5934752 0.83 WNT3A (0.53) MAPTLMNAGRM4KCNQ3KCNQ2
SCHEMBL5934343 0.82 RAB9A (0.58) MEN1KMT2AMAPTKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1575918-A2 SUBSTITUTED BIARYL-4-CARBOXYLIC ACID ARYLAMIDE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS NEUROGEN CORPORATION (US) 2005-09-21 — — EP claimed
WO-2004056774-A2 SUBSTITUTED BIPHENYL-4-CARBOXYLIC ACID ARYLAMIDE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS NEUROGEN CORPORATION (US) 2004-07-08 — — WO claimed
US-20060100245-A1 Substituted biphenyl-4-carboxylic acid arylamide analogues NEUROGEN CORPORATION (US) 2006-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100245-A1 Substituted biphenyl-4-carboxylic acid arylamide analogues HCAR2, AHR, HCAR3 MEN1 4851/4885KMT2A 1306/4885MAPT 3567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback